The ARPC1B Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the ARPC1B gene has been disrupted via CRISPR/Cas9-mediated gene targeting. This product comprises a heterogeneous pool of HT29 cells carrying diverse loss-of-function alleles, eliminating the need for single-cell cloning while providing a robust model for studying actin cytoskeleton dynamics. The polyclonal format ensures genetic diversity within the population, enabling researchers to assess broad phenotypic consequences of ARPC1B deficiency without clonal artifacts.
The host cell line HT29 is a well-characterized epithelial cell model derived from a primary colorectal adenocarcinoma of a 44-year-old Caucasian female. HT29 cells exhibit typical epithelial morphology and are extensively used to investigate colorectal cancer pathogenesis, cell adhesion, and tumor metastasis. Their robust growth and amenability to genetic manipulation make them a versatile platform for generating knockout models to examine actin-dependent processes such as migration and invasion.
ARPC1B encodes the p41-ARC subunit of the Arp2/3 complex, a heptameric assembly that nucleates branched actin filaments. The Arp2/3 complex is activated by nucleation-promoting factors including WASP family proteins (WAS, WAVE1-3), which are regulated by Rho GTPases CDC42 and RAC1. Additional upstream regulators include PIP2, NCK1, and ABL1. Downstream, ARPC1B-dependent actin polymerization drives lamellipodia formation, cell protrusions, invadopodia biogenesis, and endocytic vesicle trafficking. ARPC1B interacts with other complex subunits??ARPC1A, ARPC2, ARPC3, ARPC4, ARPC5??as well as ACTR2, ACTR3, and cortactin, positioning it as a critical node in the WASP/WAVE?CArp2/3 signaling axis.
In HT29 cells, ARPC1B knockout disrupts the Arp2/3 complex??s ability to generate branched actin networks, impairing lamellipodia-driven motility and cell-substrate adhesion. This makes the model particularly valuable for dissecting mechanisms of colorectal cancer metastasis, where actin remodeling is essential for invasive behavior. Furthermore, inherited ARPC1B mutations are linked to immunodeficiency 71, highlighting shared cytoskeletal defects between immune and epithelial cells. By ablating ARPC1B in a cancer cell line, researchers can probe how loss of this actin regulator influences tumor cell invasion, endocytic trafficking, and sensitivity to cytoskeletal-targeted therapeutics.
Typical experimental applications include western blotting to confirm ARPC1B depletion, immunofluorescence with phalloidin to visualize F-actin organization, scratch-wound migration assays to measure motility, Matrigel-coated Transwell invasion assays to assess invasiveness, and transferrin uptake assays to monitor endocytosis. Flow cytometry can analyze cell surface marker expression, co-immunoprecipitation assess Arp2/3 complex integrity, and RT-qPCR quantify ARPC1B mRNA levels. The polyclonal population is well-suited for drug screens targeting actin-related pathways and for mechanistic studies of WASP/WAVE?CRho GTPase signaling. For further technical details or support, please contact Ascent Research.
